Pan Lung Cancer PCR panel for NSCLC biomarker detection

The Pan Lung Cancer PCR Panel is a real-time qPCR assay that offers comprehensive detection of a broad range of key mutations involved in lung cancer, enabling early diagnosis and better treatment planning. It helps clinicians identify critical mutations (e.g., EGFR, KRAS, ALK, ROS1) that guide targeted therapies, including immunotherapy. The panel offers a cost-effective, quick testing option for detecting multiple mutations in a single test, addressing the challenge of needing multiple tests for different mutations.

Benefits of the Pan Lung Cancer PCR Panel

• Comprehensive biomarker detection – identifies 167 variants (85 DNA mutations, 82 RNA fusions) in 11 key genes (EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1, NTRK2, NTRK3).
• Supports targeted therapy selection – multiple biomarkers in a single PCR run, helping match non-small cell lung cancer patients with the most effective treatments.
• Fast and cost-effective testing – provides quick, accurate results at a lower cost than next-generation sequencing.
• High sensitivity and specificity – uses real-time qPCR technology to deliver reliable mutation and fusion detection, even with limited sample input.
• Laboratory-friendly workflow – designed for in vitro diagnostics (IVD), enabling efficient, streamlined testing by trained professionals.

Applications of the Pan Lung Cancer PCR Panel

• Non-Small Cell Lung Cancer (NSCLC) biomarker detection
• Companion diagnostics for targeted therapies (EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1/2/3)
• Mutation screening for clinical and translational research
• Personalised treatment selection for lung cancer patients
• Cost-effective and rapid molecular testing in oncology labs

Specifications

Materials for download

AmoyDxPan Lung Cancer PCR Panel brochure

AmoyDx Pan Lung Cancer PCR Panel user manual